Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer

Sang- Uk Woo, Jeoug Won Bae, H. G. Kim, S. H. Choi, D. H. Kang, Jae Bok Lee, B. W. Koo

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Several in vitro chemosensitivity tests have been developed to predict the chemotherapeutic response of tumours prior to initiation of individualized treatment for breast cancer. This study investigated whether the in vitro chemosensitivity response of cell lines derived from breast cancer patients was affected by HER2/neu expression. We cultured breast cancer cell lines from 50 patients and the adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was performed with 5-fluorouracil, gemcitabine, docetaxel, doxorubicin, methotrexate, vinorelbine and paclitaxel. cell death rate (32.4%) with the narrowest range of cytotoxic effects (7.3 - 65.7%). In addition, gemcitabine showed significantly greater activity in HER2/neu-positive patients. In contrast, docetaxel was significantly less effective in HER2/ neu-positive patients. No significant correlation was found between the other agents and HER2/neu expression. The use of the ATP-CRA test for metastatic tissue from patients with recurrent disease might be a useful approach to determine the most effective chemotherapy regimen.

Original languageEnglish
Pages (from-to)753-761
Number of pages9
JournalJournal of International Medical Research
Volume35
Issue number6
DOIs
Publication statusPublished - 2007 Jan 1

Keywords

  • 5-Flourouracil
  • Anticancer Agents
  • Breast cancer
  • Chemosensitivity
  • Doxorubicin
  • HER2/neu
  • Hormone receptor
  • Methotrexate
  • Vinorelbine

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer'. Together they form a unique fingerprint.

  • Cite this